What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes

NCT07210034 | Not Yet Recruiting DMC

• 1 other identifier: HALP-MDS
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

to investigate prognostic significance of many factors in MDS including HALP score ( haemoglobin level, albumin level, lymphocyte, platelets), monocytopenia, hyperfibrinogenemia and AST/ALT ratio in patients with MDS at Assiut University Hospital. And to study overall survival and leukemia free survival rates in MDS patients.

Conditions

Myelo Dysplastic Syndrome

Outcome Measures

Primary Outcomes (1)

• prognostic significance of many factors in MDS

  to investigate prognostic significance of many factors in MDS including HALP score ( haemoglobin level, albumin level, lymphocyte, platelets), in patients with MDS at Assiut University Hospital HALP : a derived value from a formula: Hemoglobin (g/L) × Albumin (g/L) × Lymphocytes (/L) / Platelets (/L)

  Two years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults (≥18 years old) diagnosed with MDS according to WHO criteria

You may qualify if:

• Adults (≥18 years old) diagnosed with MDS according to WHO criteria
• Availability of complete medical records including laboratory data for hemoglobin, albumin, lymphocyte count, platelet count, monocyte count, fibrinogen level, AST and ALT
• Patients who were followed for at least 12 months post-diagnosis or until death

You may not qualify if:

• Patients with active infections, liver cirrhosis, chronic inflammatory diseases, or concurrent malignancies at time of diagnosis
• Incomplete laboratory or clinical data
• Patients lost to follow-up within less than 3 months of diagnosis

Sponsors & Collaborators

• Assiut University: lead

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident at internal medicine department

Study Record Dates

• First Submitted: September 29, 2025
• First Posted: October 7, 2025
• Study Start: January 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): March 1, 2028
• Last Updated: October 7, 2025

Record last verified: 2025-09